Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R34 Clinical Trial Optional)
ID: 336743Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $450K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336743
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) aimed at enhancing the uptake and use of the dapivirine vaginal ring for HIV prevention. This initiative seeks to advance research on understanding the multilevel facilitators and barriers to the use of the vaginal ring, develop interventions to support its uptake and persistent use, and test implementation strategies for optimal delivery. The FOA is significant as it addresses critical public health needs in HIV prevention, with an award ceiling of $450,000 and no cost-sharing or matching requirements. Interested applicants can reach out to Dr. Teri Senn at teri.senn@nih.gov or by phone at 301-761-7852 for further information, with the FOA expected to be published in Winter 2022 and applications due in Summer 2022.

    Point(s) of Contact
    Teri Senn, Ph.D.
    (301) 761-7852
    teri.senn@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) aimed at improving the uptake and use of the dapivirine vaginal ring for HIV prevention. This initiative seeks to advance research on understanding the multilevel facilitators and barriers to the use of the vaginal ring, develop interventions to enhance its uptake and consistent use, and test implementation strategies for optimal delivery. The anticipated funding amount for this grant is up to $500,000, with the FOA expected to be published in Winter 2022 and applications due in Summer 2022. Interested applicants can reach out to Dr. Teri Senn at teri.senn@nih.gov or by phone at 301-761-7852 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) aimed at improving the uptake and use of the dapivirine vaginal ring for HIV prevention. This initiative seeks to advance research on the barriers and facilitators to the use of the vaginal ring, develop supportive interventions, and test implementation strategies for its optimal delivery. The anticipated FOA will utilize the R21 activity code, with an award ceiling of $275,000, and is expected to be published in Winter 2022, with applications due in Summer 2022. Interested applicants can reach out to Dr. Teri Senn at teri.senn@nih.gov or by phone at 301-761-7852 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)" under the National Institute of Mental Health (NIMH). This initiative aims to support innovative research focused on optimizing HIV prevention and care, emphasizing the understanding of behavioral and social science factors that influence the HIV continuum, including intervention efficacy trials and implementation science studies. The program is critical for advancing national efforts to address HIV effectively, promoting community engagement and multidisciplinary collaboration to achieve equitable health outcomes for diverse populations. Interested applicants can find more information and application details at the provided link, with a submission deadline of January 9, 2026, and no cost-sharing or matching requirements.
    Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.